Developer docs
API playgroundTry for free, no card

Search company profiles

invoX Pharma

Full company profile

uuid00091qz

Namestring
invoX Pharma
Legal namestring
invoX Pharma Limited
Websiteurl
invoxpharma.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

invoX Pharma is a privately held, UK-incorporated biopharmaceutical company founded in March 2021 and headquartered operationally at the Bioville campus in Diepenbeek, Belgium, with a registered office in London. The company is built around Softhaler®, a proprietary next-generation soft-mist inhalation (SMI) platform that mechanically converts propellant-free, water-based liquid formulations into ultra-fine mist for deep-lung delivery. The platform supports both innovative and generic drug-device combination products and is positioned to address indications including COPD, asthma, pulmonary arterial hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis, with research extending into delivery of peptides, nucleic acids, enzymes, and antibodies.

invoX monetises the platform through four interlocking streams: co-development partnerships with pharmaceutical and biotech firms that leverage Softhaler® for late-stage or approved respiratory medicines; licensing of internal pipeline programmes and platform technology; contract manufacturing services spanning device manufacture, assembly, sterile fill & finish, and packaging from development through commercial scale; and, prospectively, commercialisation of generic and innovative drug-device combination products. The company operates a unique end-to-end supply chain with its own bespoke manufacturing equipment, and in October 2024 designated H&T Presspart (Heitkamp & Thumann Group) as its industrialisation and manufacturing partner, with sub-assembly production in a dedicated clean room in Tarragona, Spain.

In March 2023, invoX acquired US-based F-star Therapeutics Inc. for $161 million, expanding its pipeline into head and neck cancer therapeutics and adding a US operating footprint. The company also holds a minor collaboration with Insilico Medicine (October 2023) for deep learning applications in drug discovery. invoX serves a narrow enterprise customer base — primarily large pharmaceutical and biotech counterparties — and pursues lead generation through a business development team and presence at major industry conferences including BIO, ERS, CPHI, PODD, Bio-Europe, Jefferies Healthcare Conference, and DDL.

Short descriptiontext

invoX Pharma is a private biopharmaceutical company that develops and partners drug-device combination products built on its proprietary Softhaler® soft-mist inhalation platform, targeting chronic respiratory diseases for pharmaceutical and biotech partners globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDiepenbeek, Belgium
HQ citystring
Diepenbeek
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
soft-mist inhalation, respiratory drug delivery, drug-device combination, inhalation therapy platform, biopharmaceutical development
Industry4 codes
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Surgical & Medical Instruments & Apparatus3841
Product category
Respiratory Drug-Device Combination Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Co-development Partnerships
TypeLicensing Royalties
Description

Revenue generated through co-development partnerships where partners leverage the Softhaler® SMI platform for their late-stage or approved medicines. Partners can deliver innovative inhalation products for lifecycle management of existing products.

invoxpharma.com
2Pipeline Licensing
TypeLicensing Royalties
Description

Licensing of internal pipeline programs to external partners. invoX offers both unpartnered programs and technology capabilities available for out-licensing.

invoxpharma.com
3Contract Manufacturing Services
TypeManaged Services
Description

Supply chain services covering development to pilot scale and pilot scale to commercial supply, across all aspects of device manufacture, assembly, sterile fill & finish, and product packaging.

invoxpharma.com
4Generic Drug-Device Products
TypeHardware Sales
Description

Commercialization of generic and innovative drug-device combination products using the Softhaler® platform. First-to-market generic solution opportunities.

invoxpharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Softhaler®
Description

A next-generation soft-mist inhalation device platform that uses differentiated technology to deliver propellant-free liquid-based formulation to the lung.

invoxpharma.com
Core offering1 text field

invoX Pharma develops and manufactures proprietary soft-mist inhalation drug-device combination products based on its Softhaler® platform, targeting respiratory diseases including COPD, asthma, PAH, cystic fibrosis, and idiopathic pulmonary fibrosis. The company offers co-development partnerships, platform licensing, contract manufacturing services, and an internal pipeline of generic and innovative inhaled therapeutics, including biologics and nucleic acids.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Better lung delivery and less deposition in mouth or at back of throat compared to other inhalers
+1 more record
Product overview1 text field

invoX Pharma is a research-driven biopharmaceutical company that operates as a platform-based business centered on its proprietary Softhaler® soft-mist inhalation device. The Softhaler® platform serves as the core technology for delivering propellant-free liquid-based formulations to the lungs. The company combines this device platform with a pipeline of generic and innovative drug-device combination products targeting respiratory diseases including COPD, asthma, PAH, CF, and IPF. The company also conducts biological molecule delivery research (peptides, nucleic acids, enzymes, antibodies) and offers platform partnering services for co-development and licensing. A key strategic strength is their end-to-end supply chain for complex drug-device manufacturing and development, with manufacturing partnerships including H&T Presspart for device sub-assembly production.

Product and service2 records
1Softhaler® Soft-Mist Inhalation Platform
CategoryDrug-Device Combination Platform
Description

A next-generation soft-mist inhalation (SMI) device platform that mechanically converts liquid formulations into ultra-fine mist for propellant-free, deep lung delivery, supporting small molecules and complex biologics such as peptides, nucleic acids, enzymes, and antibodies. It is offered to pharmaceutical and biotech partners for generic and innovative drug-device combination products.

2Respiratory Drug Pipeline
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-04
Description

Strategic collaboration where H&T Presspart manufactures the device sub-assembly for commercialization of invoX's Softhaler® soft mist inhalation device. H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain. This is invoX's designated industrialisation and manufacturing partnership.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Boehringer Ingelheim
TypeDirect peer
Description

Boehringer Ingelheim's Respimat is the established soft-mist inhaler (SMI) platform powering blockbusters such as Spiriva. As the dominant SMI incumbent, it is the most directly comparable competitor to invoX's Softhaler® platform in respiratory drug-device delivery.

TypeDirect peer
Description

Vectura is a specialist inhalation drug-device CDMO and development company offering DPI, nebulizer, and SMI platforms to partners. It is a direct comparable as a platform-based inhalation delivery business serving pharma partners, the same business model invoX pursues with Softhaler®.

TypeDirect peer
Description

Hovione is a CDMO with strong capabilities in inhalation drug product development and manufacturing, including particle engineering for DPI/nebulizer formulations. It is comparable to invoX on the contract manufacturing and formulation side of the inhalation value chain.

TypeDirect peer
Description

Aptar Pharma is a leading drug delivery device manufacturer with significant inhalation platform offerings (e.g., pMDI valves, DPI devices). It is a direct peer as a device-platform supplier serving the same respiratory pharma customer base invoX targets with Softhaler®.

TypeDirect peer
Description

Nemera designs and manufactures drug delivery devices including inhalation and nasal platforms for pharma partners. It overlaps with invoX on device-platform partnering for respiratory and combination products.

TypeBroad incumbent
Description

Catalent is a large CDMO offering inhalation development and manufacturing services alongside a much broader pharma services portfolio. It is comparable to invoX's contract manufacturing and supply-chain services but at far greater scale and breadth.

TypeBroad incumbent
Description

GSK is a top-three respiratory pharma major with proprietary inhaler platforms (e.g., Ellipta DPI) and a large commercial respiratory franchise. It is a broad incumbent competitor for both the Softhaler® platform's pharma partners and the same patient indications (COPD, asthma).

TypeBroad incumbent
Description

AstraZeneca is a leading respiratory pharma player with products across COPD, asthma, and severe asthma, and operates inhalation device platforms via partners. It is comparable as a major incumbent whose franchise and partnerships invoX would compete against for Softhaler® adoption.

TypeEmerging player
Description

Pulmatrix is a clinical-stage biopharma developing inhaled therapies for respiratory and infectious diseases using its iSPERSE dry powder technology. It is comparable as a smaller, emerging player focused on inhaled drug delivery for serious respiratory indications.

10Aradigm
TypeEmerging player
Description

Aradigm developed the AERx inhaled drug delivery platform and pursued inhaled liposomal therapies for respiratory disease. It is comparable as an emerging/specialized player in the inhaled respiratory therapeutics space, though narrower in platform scope than invoX.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

invoX Pharma

Respiratory Drug-Device Combination Productsinvoxpharma.com

invoX Pharma is a private biopharmaceutical company that develops and partners drug-device combination products built on its proprietary Softhaler® soft-mist inhalation platform, targeting chronic respiratory diseases for pharmaceutical and biotech partners globally.

What invoX Pharma does

invoX Pharma is a privately held, UK-incorporated biopharmaceutical company founded in March 2021 and headquartered operationally at the Bioville campus in Diepenbeek, Belgium, with a registered office in London. The company is built around Softhaler®, a proprietary next-generation soft-mist inhalation (SMI) platform that mechanically converts propellant-free, water-based liquid formulations into ultra-fine mist for deep-lung delivery. The platform supports both innovative and generic drug-device combination products and is positioned to address indications including COPD, asthma, pulmonary arterial hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis, with research extending into delivery of peptides, nucleic acids, enzymes, and antibodies.

invoX monetises the platform through four interlocking streams: co-development partnerships with pharmaceutical and biotech firms that leverage Softhaler® for late-stage or approved respiratory medicines; licensing of internal pipeline programmes and platform technology; contract manufacturing services spanning device manufacture, assembly, sterile fill & finish, and packaging from development through commercial scale; and, prospectively, commercialisation of generic and innovative drug-device combination products. The company operates a unique end-to-end supply chain with its own bespoke manufacturing equipment, and in October 2024 designated H&T Presspart (Heitkamp & Thumann Group) as its industrialisation and manufacturing partner, with sub-assembly production in a dedicated clean room in Tarragona, Spain.

In March 2023, invoX acquired US-based F-star Therapeutics Inc. for $161 million, expanding its pipeline into head and neck cancer therapeutics and adding a US operating footprint. The company also holds a minor collaboration with Insilico Medicine (October 2023) for deep learning applications in drug discovery. invoX serves a narrow enterprise customer base — primarily large pharmaceutical and biotech counterparties — and pursues lead generation through a business development team and presence at major industry conferences including BIO, ERS, CPHI, PODD, Bio-Europe, Jefferies Healthcare Conference, and DDL.

invoX Pharma firmographics

Firmographics
Name
invoX Pharma
Legal name
invoX Pharma Limited
Website
https://invoxpharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Short description
invoX Pharma is a private biopharmaceutical company that develops and partners drug-device combination products built on its proprietary Softhaler® soft-mist inhalation platform, targeting chronic respiratory diseases for pharmaceutical and biotech partners globally.
Ownership category
akta.pro rank

invoX Pharma industry classification

Industry
Product category
Respiratory Drug-Device Combination Products
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAI
Inhalers (MDI/DPI/SMI)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAIAJ
Nebulizers & Aerosol Drug Delivery Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAGAE
Inhalation & Nebulization Devices (Nebulizers, Spacers, Inhaler Accessories)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Soft-mist inhalation
  • Respiratory drug delivery
  • Drug-device combination
  • Inhalation therapy platform
  • Biopharmaceutical development

Where invoX Pharma is headquartered

Location

Headquarters

HQ city
Diepenbeek
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

invoX Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Co-development Partnerships: Revenue generated through co-development partnerships where partners leverage the Softhaler® SMI platform for their late-stage or approved medicines. Partners can deliver innovative inhalation products for lifecycle management of existing products.
  2. Pipeline Licensing: Licensing of internal pipeline programs to external partners. invoX offers both unpartnered programs and technology capabilities available for out-licensing.
  3. Contract Manufacturing Services: Supply chain services covering development to pilot scale and pilot scale to commercial supply, across all aspects of device manufacture, assembly, sterile fill & finish, and product packaging.
  4. Generic Drug-Device Products: Commercialization of generic and innovative drug-device combination products using the Softhaler® platform. First-to-market generic solution opportunities.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

invoX Pharma product offering

Product offering

Core offering

invoX Pharma develops and manufactures proprietary soft-mist inhalation drug-device combination products based on its Softhaler® platform, targeting respiratory diseases including COPD, asthma, PAH, cystic fibrosis, and idiopathic pulmonary fibrosis. The company offers co-development partnerships, platform licensing, contract manufacturing services, and an internal pipeline of generic and innovative inhaled therapeutics, including biologics and nucleic acids.

Product overview

invoX Pharma is a research-driven biopharmaceutical company that operates as a platform-based business centered on its proprietary Softhaler® soft-mist inhalation device. The Softhaler® platform serves as the core technology for delivering propellant-free liquid-based formulations to the lungs. The company combines this device platform with a pipeline of generic and innovative drug-device combination products targeting respiratory diseases including COPD, asthma, PAH, CF, and IPF. The company also conducts biological molecule delivery research (peptides, nucleic acids, enzymes, antibodies) and offers platform partnering services for co-development and licensing. A key strategic strength is their end-to-end supply chain for complex drug-device manufacturing and development, with manufacturing partnerships including H&T Presspart for device sub-assembly production.

Differentiator

Problem solved

Functional benefit

Brands

  • Softhaler®: A next-generation soft-mist inhalation device platform that uses differentiated technology to deliver propellant-free liquid-based formulation to the lung.

Products and services

  • Softhaler® Soft-Mist Inhalation Platform A next-generation soft-mist inhalation (SMI) device platform that mechanically converts liquid formulations into ultra-fine mist for propellant-free, deep lung delivery, supporting small molecules and complex biologics such as peptides, nucleic acids, enzymes, and antibodies. It is offered to pharmaceutical and biotech partners for generic and innovative drug-device combination products.
  • Respiratory Drug Pipeline

Quantifiable outcome

  • Better lung delivery and less deposition in mouth or at back of throat compared to other inhalers
  • +1 more outcomes

Companies that use invoX Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

invoX Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

invoX Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • H&T Presspart (Heitkamp & Thumann Group)coreStrategic or Co-development Partner · 4 October 2024Strategic collaboration where H&T Presspart manufactures the device sub-assembly for commercialization of invoX's Softhaler® soft mist inhalation device. H&T Presspart will mould components and produce sub-assemblies in a dedicated clean room at their site in Tarragona, Spain. This is invoX's designated industrialisation and manufacturing partnership.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

invoX Pharma competitors and assessment

Company assessment

Direct peers

  • Boehringer Ingelheim: Boehringer Ingelheim's Respimat is the established soft-mist inhaler (SMI) platform powering blockbusters such as Spiriva. As the dominant SMI incumbent, it is the most directly comparable competitor to invoX's Softhaler® platform in respiratory drug-device delivery.
  • Vectura Group: Vectura is a specialist inhalation drug-device CDMO and development company offering DPI, nebulizer, and SMI platforms to partners. It is a direct comparable as a platform-based inhalation delivery business serving pharma partners, the same business model invoX pursues with Softhaler®.
  • Hovione: Hovione is a CDMO with strong capabilities in inhalation drug product development and manufacturing, including particle engineering for DPI/nebulizer formulations. It is comparable to invoX on the contract manufacturing and formulation side of the inhalation value chain.
  • Aptar Pharma: Aptar Pharma is a leading drug delivery device manufacturer with significant inhalation platform offerings (e.g., pMDI valves, DPI devices). It is a direct peer as a device-platform supplier serving the same respiratory pharma customer base invoX targets with Softhaler®.
  • Nemera: Nemera designs and manufactures drug delivery devices including inhalation and nasal platforms for pharma partners. It overlaps with invoX on device-platform partnering for respiratory and combination products.

Broad incumbents

  • Catalent: Catalent is a large CDMO offering inhalation development and manufacturing services alongside a much broader pharma services portfolio. It is comparable to invoX's contract manufacturing and supply-chain services but at far greater scale and breadth.
  • GlaxoSmithKline (GSK): GSK is a top-three respiratory pharma major with proprietary inhaler platforms (e.g., Ellipta DPI) and a large commercial respiratory franchise. It is a broad incumbent competitor for both the Softhaler® platform's pharma partners and the same patient indications (COPD, asthma).
  • AstraZeneca: AstraZeneca is a leading respiratory pharma player with products across COPD, asthma, and severe asthma, and operates inhalation device platforms via partners. It is comparable as a major incumbent whose franchise and partnerships invoX would compete against for Softhaler® adoption.

Emerging players

  • Pulmatrix: Pulmatrix is a clinical-stage biopharma developing inhaled therapies for respiratory and infectious diseases using its iSPERSE dry powder technology. It is comparable as a smaller, emerging player focused on inhaled drug delivery for serious respiratory indications.
  • Aradigm: Aradigm developed the AERx inhaled drug delivery platform and pursued inhaled liposomal therapies for respiratory disease. It is comparable as an emerging/specialized player in the inhaled respiratory therapeutics space, though narrower in platform scope than invoX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

invoX Pharma social profiles

Digital presence

invoX Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

invoX Pharma leadership team

Management profile

Number of profiles

Profiles11 records

invoX Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

invoX Pharma M&A and investment

M&A and investment

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about invoX Pharma

What does invoX Pharma do?

invoX Pharma develops and manufactures proprietary soft-mist inhalation drug-device combination products based on its Softhaler® platform, targeting respiratory diseases including COPD, asthma, PAH, cystic fibrosis, and idiopathic pulmonary fibrosis. The company offers co-development partnerships, platform licensing, contract manufacturing services, and an internal pipeline of generic and innovative inhaled therapeutics, including biologics and nucleic acids.

Is invoX Pharma a public or private company?

invoX Pharma is a private company. It is classified as unknown and is currently operating.

When was invoX Pharma founded?

invoX Pharma was founded in 2021. It employs 51 to 100 people.

Where is invoX Pharma based?

invoX Pharma is headquartered in Diepenbeek, Belgium, in the Europe region.

How does invoX Pharma make money?

Four revenue lines are on record. Co-development Partnerships are the primary driver. The others are pipeline Licensing, contract Manufacturing Services and generic Drug-Device Products.

Who are invoX Pharma's main competitors?

Direct peers on record are Boehringer Ingelheim, Vectura Group, Hovione, Aptar Pharma and Nemera. Broad incumbents are Catalent, GlaxoSmithKline (GSK) and AstraZeneca. Emerging players are Pulmatrix and Aradigm.

Does invoX Pharma have an API?

No public API is recorded for invoX Pharma.

What industry is invoX Pharma in?

invoX Pharma's product category is Respiratory Drug-Device Combination Products. Its primary akta.pro industry code is HLAHAIAI, Inhalers (MDI/DPI/SMI), with a secondary code of HLAHAIAJ, Nebulizers & Aerosol Drug Delivery Systems. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Trend Insights: The Impact of Recent Advances on the Head and Neck Cancer Therapeutics MarketThe head and neck cancer therapeutics market is projected to reach $3.13 billion by 2030, growing at a compound annual growth rate of 10.8%, driven by advancements in targeted immunotherapies, AI-driven diagnostics, and personalized medicine strategies. In March 2023, UK-based InvoX Pharma Ltd. acquired US-based F-star Therapeutics Inc. for $161 million to expand its cancer therapeutics portfolio in the head and neck cancer space. Additionally, US-based Coherus BioSciences Inc. received FDA approval in October 2023 for its drug Loqtorzi as a first-line treatment for adults with metastatic or recurrent nasopharyngeal carcinoma.BenzingaWhy F-Star Therapeutics Shares Are Moving HigherF-Star Therapeutics announced that CFIUS has cleared the proposed acquisition by invoX Pharma, marking the final regulatory approval needed to complete the merger. The tender offer is scheduled to expire Wednesday at 5 p.m. ET, and shares surged 16.6% to $7.11 following the announcement. F-Star is a clinical-stage biopharmaceutical company developing next-generation immunotherapies for cancer patients.GlobeNewswireinvoX Pharma and F-star Therapeutics issue Joint StatementinvoX Pharma and F-star Therapeutics are negotiating a mitigation agreement with CFIUS to address national security concerns about their pending transaction. The parties aim to remove CFIUS's Interim Order and complete the deal by January 31, 2023, unless extended. No assurance is given that an agreement will be reached.PR NewswireINVESTIGATION NOTICE: Halper Sadeh LLP Investigates DRE, RDUS, FSTX, RADA, USAKHalper Sadeh LLP, an investor rights law firm, announced investigations into five companies regarding potential federal securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The investigations cover Duke Realty's sale to Prologis, Radius Health's sale to Gurnet Point Capital and Patient Square Capital, F-star Therapeutics' sale to invoX Pharma, RADA Electronic Industries' merger with Leonardo DRS, and USA Truck's sale to DB Schenker. The law firm indicated it may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.BioSpaceinvoX Pharma Commences Tender Offer for F-star Therapeutics, Inc.invoX Pharma, a Sino Biopharm subsidiary, commenced a cash tender offer for all F-star Therapeutics shares at $7.12 per share on July 7, 2022. The offer expires August 3, 2022, with a merger to follow if stockholders tender over 50% of shares.PR NewswireInvestor Alert - The M&A Class Action Firm Announces an Investigation of F-star Therapeutics, Inc. - FSTXMonteverde & Associates PC, a securities class action law firm, announced an investigation into F-star Therapeutics, Inc. regarding its proposed acquisition by invoX Pharma through a tender offer. Under the terms of the deal, FSTX shareholders would receive $7.12 in cash per share. The law firm is reaching out to FSTX shareholders to inform them of the investigation and offer free information about their potential legal options.PR NewswireINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAKInvestor rights law firm Halper Sadeh LLP announced investigations into four pending acquisitions for potential violations of federal securities laws and/or breaches of fiduciary duties: Radius Health's sale to Gurnet Point Capital and Patient Square Capital for $10.00 per share plus a Contingent Value Right, F-star Therapeutics' sale to invoX Pharma for $7.12 per share, Zendesk's sale to Permira and Hellman & Friedman LLC for $77.50 per share, and USA Truck's sale to DB Schenker for $31.72 per share. The firm is contacting shareholders of each company to discuss their legal rights and options, potentially seeking increased consideration, additional disclosures, or other relief on their behalf.PR NewswireSHAREHOLDER ALERT: Weiss Law Investigates F-star Therapeutics, Inc.Weiss Law has launched an investigation into the board of directors of F-star Therapeutics, Inc. regarding the proposed acquisition by invoX Pharma via tender offer. Under the deal terms, F-star shareholders would receive $7.12 in cash per share, valuing the transaction at approximately $161 million. The law firm is examining whether the board acted in shareholders' best interests, given that the $7.12 per-share consideration falls significantly below the $30.00 median analyst price target and the $35 per-share price target set by at least one analyst.GlobeNewswireinvoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical ProgramsinvoX Pharma, a Sino Biopharm subsidiary, agreed to acquire F-star Therapeutics for $7.12 per share, valuing the company at approximately $161 million. The all-cash deal, expected to close in the second half of 2022, adds F-star's tetravalent bispecific antibody platform to invoX's oncology pipeline.PR NewswireShareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transaction with invoXLaw firm Ademi LLP announced an investigation into F-star Therapeutics, Inc. (NASDAQ:FSTX) regarding its transaction with invoX, alleging possible breaches of fiduciary duty and that shareholders will receive only $7.12 per share, valuing the company at approximately $161 million. The law firm claims the transaction agreement unreasonably limits competing bids by imposing a significant penalty if F-star accepts a superior offer, and that F-star insiders will receive substantial benefits under change of control arrangements. Ademi LLP is inviting F-star shareholders to join potential legal action at no cost.